No­var­tis team scores a pi­o­neer­ing first in car­dio R&D. But can they sell it?

No­var­tis is fac­ing an­oth­er block­buster chal­lenge of glob­al pro­por­tions.

How do you mar­ket a heart drug with re­al but clear­ly lim­it­ed health ben­e­fits? One where …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER